Lexicon Pharmaceuticals (LXRX) Short-term Investments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Short-term Investments for 17 consecutive years, with $132.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments changed 0.47% year-over-year to $132.6 million; the TTM figure through Mar 2026 stood at $132.6 million (changed 0.47% YoY), while the FY2025 annual figure was $61.9 million, down 63.86% from the prior year.
• Short-term Investments advanced to $132.6 million in Q1 2026 per LXRX's latest filing, from $61.9 million in the prior quarter.
• Across five years, Short-term Investments topped out at $274.3 million in Q2 2024 and bottomed at $27.0 million in Q1 2022.
• Historically, Short-term Investments has averaged $135.0 million across 5 years, with a median of $132.0 million in 2025.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 307.53% — and 2025, when it sank 70.38%.
• Lexicon Pharmaceuticals' Short-term Investments stood at $92.0 million in 2022, then jumped by 60.37% to $147.6 million in 2023, then climbed by 16.09% to $171.3 million in 2024, then plunged by 63.86% to $61.9 million in 2025, then surged by 114.15% to $132.6 million in 2026.
• Business Quant data shows LXRX's Short-term Investments at $132.6 million in Q1 2026, $61.9 million in Q4 2025, and $66.3 million in Q3 2025.